Results 71 to 80 of about 1,772,527 (156)

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper   +27 more
wiley   +1 more source

What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?

open access: yes, 2021
Hypomethylating agents (HMAs) are the standard of care for higher risk MDS (HR-MDS) patients. The current dogma is to begin HMA therapy in all HR-MDS patients at the time of initial diagnosis.
Al Ali, Najla   +21 more
core   +1 more source

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo   +7 more
wiley   +1 more source

Real-world outcomes of venetoclax plus hypomethylating agents in BPDCN across treatment lines

open access: yesHaematologica
Not available.
Erica N. Lamkin   +4 more
doaj   +1 more source

Investigating drug response and resistance to IDH1R132H inhibition and hypomethylating agents in AML

open access: yes, 2020
© 2020 Emily Simone GruberMutations in epigenetic regulators frequently occur in AML. Furthermore, the epigenetic landscape is typically dysregulated in AML. Targeted epigenetic therapeutics that directly inhibit mutant epigenetic oncogenic drivers, such
Gruber, Emily Simone
core   +1 more source

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

open access: yesCell Death and Disease
Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies and seriously threaten people’s health. Current therapies include bone marrow transplantation and several hypomethylating agents.
Li Liu   +9 more
doaj   +1 more source

Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents

open access: yes, 2015
Patients with higher-risk MDS have an abysmal survival record and should be started immediately on therapy, the most common of which being the hypomethylating agents, azacitidine or decitabine.
Sekeres, Mikkael A.
core   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

open access: yesCancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu   +8 more
wiley   +1 more source

A critical role of epigenetic inactivation of miR-9 in EVI1high pediatric AML

open access: yesMolecular Cancer, 2019
Ectopic Viral Integration site 1 (EVI1) upregulation is implicated in 10–25% of pediatric acute myeloid leukemia (AML) and has an inferior outcome with current chemotherapy regimens. Here we report that EVI1 upregulation is associated with methylation of
Nupur Mittal   +7 more
doaj   +1 more source

T‐Cell Response After SARS‐CoV‐2 Vaccination in Patients With Hematological Malignancy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized.
L. S. Boerenkamp   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy